← Leaderboards
Kurt Fisher
University Of Nebraska Medical Center
$2,635,486
Attributed
$2,635,486
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $720.3K · FY2018–25$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,635,486 · 3
By mechanism
K08$1,187,910 · 1
R37$885,766 · 1
P20$561,810 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Nebraska Medical Center
Same institution · by research overlap
- Joyce C Solheim$4,238,815
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorKras2 GenePpar GammaTranscription FactorMetabolismProteinsGrowthOverexpressionProtein FamilyTranscription CoactivatorMetastatic ColorectalMutationMetastatic Neoplasm To The LiverMutantGenesGene ExpressionMass Spectrum AnalysisGenetic TranscriptionColorectal CancerHomeostasisMouse ModelColonMetabolicKnock-Out
Grant awards (9)
Assessment of strategies for targeting transcriptional co-activators in colorectal cancer$446,399
R37 · FY2025 · CA · contact PI
Assessment of strategies for targeting transcriptional co-activators in colorectal cancer$439,367
R37 · FY2024 · CA · contact PI
Novel Mechanisms of Inhibiting Transcriptional Coactivators for Anti-Cancer Therapy in Colorectal Cancer$280,905
P20 · FY2024 · GM · contact PI
Novel Mechanisms of Inhibiting Transcriptional Coactivators for Anti-Cancer Therapy in Colorectal Cancer$280,905
P20 · FY2023 · GM · contact PI
The role of PGC1beta and ERRalpha as novel targets for therapy in colorectal cancer$237,582
K08 · FY2022 · CA · contact PI
The role of PGC1beta and ERRalpha as novel targets for therapy in colorectal cancer$237,582
K08 · FY2021 · CA · contact PI
The role of PGC1beta and ERRalpha as novel targets for therapy in colorectal cancer$237,582
K08 · FY2020 · CA · contact PI
The role of PGC1beta and ERRalpha as novel targets for therapy in colorectal cancer$237,582
K08 · FY2019 · CA · contact PI
The role of PGC1beta and ERRalpha as novel targets for therapy in colorectal cancer$237,582
K08 · FY2018 · CA · contact PI